Blood Cancer Journal (Dec 2021)
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
- Carlos Fernández de Larrea,
- Robert Kyle,
- Laura Rosiñol,
- Bruno Paiva,
- Monika Engelhardt,
- Saad Usmani,
- Jo Caers,
- Wilson Gonsalves,
- Fredrik Schjesvold,
- Giampaolo Merlini,
- Suzanne Lentzch,
- Enrique Ocio,
- Laurent Garderet,
- Philippe Moreau,
- Pieter Sonneveld,
- Ashraf Badros,
- Gösta Gahrton,
- Hartmut Goldschmidt,
- Sascha Tuchman,
- Hermann Einsele,
- Brian Durie,
- Baldeep Wirk,
- Pellegrino Musto,
- Patrick Hayden,
- Martin Kaiser,
- Jesús San Miguel,
- Joan Bladé,
- S. Vincent Rajkumar,
- Maria Victoria Mateos
Affiliations
- Carlos Fernández de Larrea
- Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
- Robert Kyle
- Internal Medicine, Division of Hematology, Mayo Clinic
- Laura Rosiñol
- Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
- Bruno Paiva
- Centro de Investigacion Medica Aplicada Instituto de Investigacion Sanitaria de Navarra, Clínica Universidad de Navarra
- Monika Engelhardt
- Medical Department, Hematology, Oncology & Stem Cell Transplantation, University Medical Center Freiburg
- Saad Usmani
- Hematogic Oncology and Blood Disorders, Levine Cancer Institute
- Jo Caers
- Department of Hematology, CHU de Liège
- Wilson Gonsalves
- Internal Medicine, Division of Hematology, Mayo Clinic
- Fredrik Schjesvold
- Oslo Myeloma Centre, Department of Hematology, Oslo University Hospital
- Giampaolo Merlini
- Department of Molecular Medicine, University of Pavia
- Suzanne Lentzch
- Department of Medicine, Columbia University
- Enrique Ocio
- Department of Hematology, Hospital Universitario de Salamanca-IBSAL, IBMCC (USAL-CSIC)
- Laurent Garderet
- Service d’Hématologie et Thérapie Cellulaire, Hôpital Saint Antoine
- Philippe Moreau
- Department of Hematology, University Hospital Nantes
- Pieter Sonneveld
- Department of Hematology, Erasmus Medical Center
- Ashraf Badros
- Greenebaum Cancer Center, University of Maryland
- Gösta Gahrton
- Department of Medicine, Karolinska Institutet
- Hartmut Goldschmidt
- Internal Medicine V, University Hospital Heidelberg
- Sascha Tuchman
- Lineberger Comprehensive Cancer Center, University of North Carolina
- Hermann Einsele
- Department of Internal Medicine II, University Hospital Würzburg
- Brian Durie
- Hematology/Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai 2 Medical Center
- Baldeep Wirk
- Bone Marrow Transplant Program, Penn State Cancer Institute
- Pellegrino Musto
- IRCCS-CROB, Referral Cancer Center of Basilicata
- Patrick Hayden
- Department of Haematology, St. James’s Hospital
- Martin Kaiser
- Myeloma Molecular Therapy Group, The Institute of Cancer Research
- Jesús San Miguel
- Centro de Investigacion Medica Aplicada Instituto de Investigacion Sanitaria de Navarra, Clínica Universidad de Navarra
- Joan Bladé
- Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
- S. Vincent Rajkumar
- Internal Medicine, Division of Hematology, Mayo Clinic
- Maria Victoria Mateos
- Department of Hematology, Hospital Universitario de Salamanca-IBSAL, IBMCC (USAL-CSIC)
- DOI
- https://doi.org/10.1038/s41408-021-00587-0
- Journal volume & issue
-
Vol. 11,
no. 12
pp. 1 – 5
Abstract
Abstract Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of ≥5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.
